• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » C4 Therapeutics completes core scientific leadership team

C4 Therapeutics completes core scientific leadership team

September 7, 2016
CenterWatch Staff

C4 Therapeutics (C4T) has announced details of the leadership team recruited to develop a new class of broadly applicable small molecule drugs for degrading disease-relevant proteins for therapeutic benefit. The leadership team includes Isabel Chiu, Ph.D., as senior vice president of Translational Sciences and Alliance Management, Stewart Fisher, Ph.D., as senior vice president of Discovery Sciences, Tim Heffernan, Ph.D., as senior vice president of Biology, and Christopher Nasveschuk, Ph.D., as vice president of Chemistry.

“Isabel, Stew, Tim, and Chris are recognized leaders in translational research, biochemistry and discovery sciences, cancer biology and chemistry. Over the past six months they have added much momentum to our science and capabilities build. Their deep expertise in drug discovery will continue to advance our development of first-in-class Degronimid molecules for the treatment of cancer and other life-threatening and life-impairing diseases,” said Andy Phillips, Ph.D., chief scientific officer of C4 Therapeutics.

Dr. Chiu most recently served as vice president of Translational and Clinical Science at Enumeral Biomedical and was previously vice president of Translational Research at AVEO Oncology. In these roles, Dr. Chiu was responsible for target and biomarker discovery, validation, preclinical development, and played key leadership roles in strategic partnerships. She also contributed to the development of numerous small molecule and antibody programs in the clinic through external collaborations and internal pipelines. She received her postdoctoral training at Johns Hopkins Medical School, holds a Ph.D. in biology from MIT, and a B.A. in biochemistry from Brandeis University.

Dr. Fisher previously held senior leadership roles at the Broad Institute and AstraZeneca across target validation, drug discovery, and clinical candidate support. Dr. Fisher started his career at Hoffmann-La Roche after completing an NIH Postdoctoral Fellowship at Harvard Medical School. He holds a Ph.D. in organic chemistry from the California Institute of Technology and a B.A. in chemistry from the University of Vermont.

Prior to joining C4 Therapeutics, Dr. Heffernan held positions of increasing responsibility at the Institute for Applied Cancer Science at MD Anderson Cancer Center. He most recently served as co-director and head of Drug Development, where he managed drug discovery and research programs from target identification through preclinical development. Previously, Dr. Heffernan led target discovery at the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute. He holds a Ph.D. in cell and molecular pathology from the University of North Carolina at Chapel Hill and performed his postdoctoral training at Dana-Farber Cancer Institute and Harvard Medical School.

Dr. Nasveschuk joined C4 Therapeutics from the Broad Institute, where he led a group of medicinal chemists in projects in the cancer, metabolism, and autophagy disease areas at the Center for the Development of Therapeutics. Prior to Broad, Dr. Nasveschuk was an integral member of the team at Constellation Pharmaceuticals where he co-invented the EZH2 inhibitor CPI-1205 and helped to discover and develop the BET inhibitor CPI-0610. He holds a Ph.D. in organic chemistry from Colorado State University and a B.S. in chemistry from Middlebury College.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing